Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial

Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial

Summary: Background: The effectiveness of combination therapy for COVID-19 pneumonia remains unclear. We evaluated favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia. Methods: In this open-label phase 3 study, hospitalized adults who were positiv...

Full description

Bibliographic Details
Main Authors: Jiro Terada, Retsu Fujita, Takuya Kawahara, Yasutaka Hirasawa, Taku Kinoshita, Yuichiro Takeshita, Yuri Isaka, Toru Kinouchi, Hiroshi Tajima, Yuji Tada, Kenji Tsushima
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:EClinicalMedicine
Subjects:
COVID-19
Camostat
Ciclesonide
Combination therapy
Favipiravir
Hospital stay
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537022002140

Internet

http://www.sciencedirect.com/science/article/pii/S2589537022002140

Similar Items